ＢＷ‐３７３Ｕ‐８６
| 分子式： | 2ClH C27H37N3O2 |
| その他の名称： | BW-373U-86 |
| 体系名： | rac-4-[(αR*)-α-[(2S*,5R*)-4-アリル-2,5-ジメチル-1-ピペラジニル]-3-ヒドロキシベンジル]-N,N-ジエチルベンズアミド・2塩酸塩 |
ＳＮＣ‐８６
| 分子式： | C27H37N3O2 |
| その他の名称： | 4-[(αR)-α-[(2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl]-3-hydroxybenzyl]-N,N-diethylbenzamide、(+)-BW-373U-86、SNC-86、N,N-Diethyl-4-[(αR)-α-[(2S)-2β,5α-dimethyl-4-allylpiperazino]-3-hydroxybenzyl]benzamide、(+)-BW-373-U-86 |
| 体系名： | 4-[(αR)-α-[(2S,5R)-4-アリル-2,5-ジメチル-1-ピペラジニル]-3-ヒドロキシベンジル]-N,N-ジエチルベンズアミド、N,N-ジエチル-4-[(αR)-α-[(2S)-2β,5α-ジメチル-4-アリルピペラジノ]-3-ヒドロキシベンジル]ベンズアミド |
BW373U86
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2014/07/08 13:19 UTC 版)
(+)BW373U86は、オピオイド系の鎮痛剤であり、科学研究に用いられる[1][2]。
- ^ Calderon SN, Rice KC, Rothman RB, Porreca F, Flippen-Anderson JL, Kayakiri H, Xu H, Becketts K, Smith LE, Bilsky EJ, Davis P, Horvath R (1997). “Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective δ agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80) and related novel nonpeptide delta opioid receptor ligands”. Journal of Medicinal Chemistry 40 (5): 695-704. doi:10.1021/jm960319n. PMID 9057856.
- ^ Thomas JB, Herault XM, Rothman RB, Atkinson RN, Burgess JP, Mascarella SW, Dersch CM, Xu H, Flippen-Anderson JL (2001). “Factors influencing agonist potency and selectivity for the opioid δ receptor are revealed in structure-activity relationship studies of the 4-(N-substituted-4-piperidinyl)arylamino-N,N-diethylbenzamides”. Journal of Medical Chemistry 44 (6): 972-987. doi:10.1021/jm000427g. PMID 11300879.
- ^ Chang KJ, Rigdon GC, Howard JL, McNutt RW (1993). “A novel, potent and selective nonpeptidic δ opioid receptor agonist BW373U86”. The Journal of Pharmacology and Experimental Therapeutics 267 (2): 852-857. PMID 8246159.
- ^ Broom DC, Nitsche JF, Pintar JE, Rice KC, Woods JH, Traynor JR (2002). “Comparison of Receptor Mechanisms and Efficacy Requirements for δ-Agonist-Induced Convulsive Activity and Antinociception in Mice”. Journal of Pharmacology and Experimental Therapeutics 303 (2): 723-729. doi:10.1124/jpet.102.036525. PMID 12388657.
- ^ Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002). “Nonpeptidic δ-opioid Receptor Agonists Reduce Immobility in the Forced Swim Assay in Rats”. Neuropsychopharmacology 26 (6): 744-755. doi:10.1016/S0893-133X(01)00413-4. PMID 12007745.
- ^ Patel HH, Hsu A, Moore J, Gross GJ (2001). “BW373U86, a δ Opioid Agonist, Partially Mediates Delayed Cardioprotection via a Free Radical Mechanism that is Independent of Opioid Receptor Stimulation”. Journal of Molecular and Cellular Cardiology 33 (8): 1455-1465. doi:10.1006/jmcc.2001.1408. PMID 11448134.
- ^ Patel HH, Hsu AK, Gross GJ (2004). “COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat”. Life Sciences 75 (2): 129-140. doi:10.1016/j.lfs.2003.10.036. PMID 15120566.
- ^ Gross ER, Hsu AK, Gross GJ (2007). “GSK3β inhibition and KATP channel opening mediate acute opioid-induced cardioprotection at reperfusion”. Basic Research in Cardiology 102 (4): 341-349. doi:10.1007/s00395-007-0651-6. PMID 17450314.
[続きの解説]
「BW373U86」の続きの解説一覧
- 1 BW373U86とは
- 2 BW373U86の概要
- BW373U86のページへのリンク
